Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA studyMarina Elena Cazzaniga, Martina Dester, Mario Airoldi et al.|The Breast|2017Cited by 23
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic ChemotherapyV. Fanotto, Giuseppe Aprile, Mario Uccello et al.|The Oncologist|2018Cited by 8
MOESM6 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Â monthsA Riccio, Giorgio Canonica, Pierluigi Mauri et al.|Figshare|2017Cited by 0
MOESM3 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 monthsA Riccio, Giorgio Walter Canonica, Pierluigi Mauri et al.|Figshare|2017Cited by 0
MOESM1 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Â monthsAnna Riccio, Giorgio Walter Canonica, Pierluigi Mauri et al.|Figshare|2017Cited by 0